In a leaked abstract, J&J's cell therapy appears to have dramatic benefits for multiple myeloma patients
Patients taking Legend Biotech and Johnson & Johnson’s cancer cell therapy Carvykti had a 74% reduction in the risk of multiple myeloma progression or death, according to a leaked abstract from an upcoming medical meeting.
The data, which emerged Tuesday night and have since been taken down, could put Carvykti ahead of competitor Abecma, a CAR-T developed by Bristol Myers Squibb and 2seventy bio, in earlier lines of treatment if and when it’s approved for those indications. The study’s results surprised analysts, with a Cowen analyst describing it as “game-changing efficacy,” and sent Legend’s shares $LEGN 14% higher after Wednesday’s opening bell.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.